Centrexion Therapeutics (PRIVATE.CNTX)

Overall impact
B (69)

Commentary

Centrexion Therapeutics is a strong overall performer. With a 'B' rating of 68.5 for overall impact (80th percentile compared to all companies), Centrexion Therapeutics ranks 72nd out of 154 industry peers, behind Adamis Pharmaceuticals, Benitec Biopharma, Aquinox Pharmaceuticals and 68 others, and ahead of Evolus, GenSight Biologics, Oyster Point Pharma and 79 others. On top material causes for Centrexion Therapeutics's industry (Pharmaceuticals & Biotech), Centrexion Therapeutics performs well in Disease Eradication (96.3 score), Technology Innovation (95.5) and Child and Maternal Health (85.6). Centrexion Therapeutics did not receive a 'D' or 'F' rating on any cause.
Impact
Cause PRIVATE.CNTX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2013
Employees
23
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
United States
Share classes
PRIVATE.CNTX
CNTX
Description
Operator of a clinical-stage biopharmaceutical company intended to address the unmet medical need for the treatment of chronic pain. The company offers services that include identifying, developing and commercializing novel, non-opioid and non-addictive therapies like a topical gel, joint or deeper tissue injection, spinal delivery and three separate oral therapies, enabling patients to have safe, effective and durable treatments.
Material causes
Ethos considers the following causes material for Centrexion Therapeutics, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.